Published in ACS Chem Neurosci on August 31, 2012
Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer's disease. Sci Rep (2016) 0.80
A potent antioxidant small molecule aimed at targeting metal-based oxidative stress in neurodegenerative disorders. Chem Commun (Camb) (2013) 0.80
Bimodal-hybrid heterocyclic amine targeting oxidative pathways and copper mis-regulation in Alzheimer's disease. Metallomics (2014) 0.75
Multi-target-directed phenol-triazole ligands as therapeutic agents for Alzheimer's disease. Chem Sci (2017) 0.75
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (2001) 36.00
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov (2004) 5.82
Long-term potentiation and memory. Physiol Rev (2004) 4.98
Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci (1998) 4.19
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol (2003) 3.58
Metals in neurobiology: probing their chemistry and biology with molecular imaging. Chem Rev (2008) 3.28
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol (2011) 2.81
Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem Rev (2006) 2.59
The metallobiology of Alzheimer's disease. Trends Neurosci (2003) 2.47
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron (2008) 2.30
Alternatives to gadolinium-based metal chelates for magnetic resonance imaging. Chem Rev (2010) 2.25
Alzheimer's disease: from pathology to therapeutic approaches. Angew Chem Int Ed Engl (2009) 2.12
Metals in Alzheimer's and Parkinson's diseases. Curr Opin Chem Biol (2008) 1.98
N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biol Psychiatry (2008) 1.93
Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des (2004) 1.90
Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer's disease? J Neurosci (2010) 1.74
Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem (2001) 1.68
Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol (2011) 1.67
Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine (2005) 1.59
Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics (2008) 1.58
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis (2010) 1.57
Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS One (2007) 1.55
Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry (2003) 1.53
The chemistry of Alzheimer's disease. Chem Soc Rev (2009) 1.40
Metals and Alzheimer's disease. J Alzheimers Dis (2006) 1.39
Mechanisms of A beta mediated neurodegeneration in Alzheimer's disease. Int J Biochem Cell Biol (2007) 1.36
Copper and zinc binding to amyloid-beta: coordination, dynamics, aggregation, reactivity and metal-ion transfer. Chembiochem (2009) 1.34
Small molecule modulators of copper-induced Abeta aggregation. J Am Chem Soc (2009) 1.30
Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease. Chem Rev (2009) 1.30
Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. Proc Natl Acad Sci U S A (2009) 1.29
Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics. Prog Neurobiol (2010) 1.29
Mechanisms of oxidative glutamate toxicity: the glutamate/cystine antiporter system xc- as a neuroprotective drug target. CNS Neurol Disord Drug Targets (2010) 1.28
Metals ions and neurodegeneration. Biometals (2007) 1.24
Abeta-mediated ROS production by Cu ions: structural insights, mechanisms and relevance to Alzheimer's disease. Biochimie (2009) 1.21
Metals and amyloid-beta in Alzheimer's disease. Int J Exp Pathol (2005) 1.19
Conformational dynamics of amyloid beta-protein assembly probed using intrinsic fluorescence. Biochemistry (2005) 1.17
Redox chemistry of copper-amyloid-beta: the generation of hydroxyl radical in the presence of ascorbate is linked to redox-potentials and aggregation state. Chembiochem (2007) 1.10
Concentration dependent Cu2+ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-beta peptide. Biochemistry (2007) 1.06
The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity. J Neurochem (2011) 1.06
Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid. Neurobiol Aging (2007) 1.04
Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease. PLoS One (2011) 1.02
A novel approach to the identification and quantitative elemental analysis of amyloid deposits--insights into the pathology of Alzheimer's disease. Biochem Biophys Res Commun (2009) 1.02
The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught? Pharmacol Res (2004) 1.02
Combating Alzheimer's disease with multifunctional molecules designed for metal passivation. Angew Chem Int Ed Engl (2007) 1.01
Elevated labile Cu is associated with oxidative pathology in Alzheimer disease. Free Radic Biol Med (2011) 1.01
Effects of cyclen and cyclam on zinc(II)- and copper(II)-induced amyloid beta-peptide aggregation and neurotoxicity. Inorg Chem (2009) 0.99
Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species. J Alzheimers Dis (2004) 0.98
Dipicolinic acid prevents the copper-dependent oxidation of low density lipoprotein. J Nutr Biochem (2003) 0.98
Increased affinity for copper mediated by cysteine 111 in forms of mutant superoxide dismutase 1 linked to amyotrophic lateral sclerosis. Free Radic Biol Med (2007) 0.95
Altering pyridinone N-substituents to optimise activity as potential prodrugs for Alzheimer's disease. Dalton Trans (2008) 0.95
Recent Development of Bifunctional Small Molecules to Study Metal-Amyloid-β Species in Alzheimer's Disease. Int J Alzheimers Dis (2010) 0.95
Lanthanide(III) complexes of tris(amide) PCTA derivatives as potential bimodal magnetic resonance and optical imaging agents. Chemistry (2009) 0.94
Challenges associated with metal chelation therapy in Alzheimer's disease. J Alzheimers Dis (2009) 0.93
Paradoxical condensation of copper with elevated beta-amyloid in lipid rafts under cellular copper deficiency conditions: implications for Alzheimer disease. J Biol Chem (2009) 0.93
Presenilins promote the cellular uptake of copper and zinc and maintain copper chaperone of SOD1-dependent copper/zinc superoxide dismutase activity. J Biol Chem (2011) 0.92
Estrogen protection in Friedreich's ataxia skin fibroblasts. Endocrinology (2011) 0.92
Probing oxidative stress: Small molecule fluorescent sensors of metal ions, reactive oxygen species, and thiols. Coord Chem Rev (2012) 0.90
The heterogeneous nature of Cu2+ interactions with Alzheimer's amyloid-β peptide. Acc Chem Res (2011) 0.89
Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Res Rev (2004) 0.89
Copper and zinc dismetabolism in the mouse brain upon chronic cuprizone treatment. Cell Mol Life Sci (2005) 0.89
Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer's brains. ACS Chem Neurosci (2011) 0.88
Amyloid-β: the seeds of darkness. Int J Biochem Cell Biol (2011) 0.87
Accumulation of copper and other metal ions, and metallothionein I/II expression in the bovine brain as a function of aging. J Chem Neuroanat (2008) 0.87
Metal-mediated formation of fibrillar ABri amyloid. J Inorg Biochem (2004) 0.83
Early detection of amyloid aggregation using intrinsic fluorescence. Biosens Bioelectron (2010) 0.83
Beta-amyloid oligomerisation monitored by intrinsic tyrosine fluorescence. Phys Chem Chem Phys (2011) 0.82
Correlation of copper interaction, copper-driven aggregation, and copper-driven h(2)o(2) formation with aβ40 conformation. Int J Alzheimers Dis (2010) 0.79
Electronic and molecular structures of the members of the electron transfer series [Cr(tbpy)3]n (n = 3+, 2+, 1+, 0): an X-ray absorption spectroscopic and density functional theoretical study. Inorg Chem (2011) 0.79
Copper modulation as a therapy for Alzheimer's disease? Int J Alzheimers Dis (2011) 0.77
Metallothionein I-II immunocytochemical reactivity in Binswanger's encephalopathy. J Alzheimers Dis (2002) 0.76
Chemical issues addressing the construction of the distal Ni[cysteine-glycine-cysteine]2- site of acetyl CoA synthase: why not copper? Inorg Chem (2009) 0.76
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron (2007) 3.98
Alternatives to gadolinium-based metal chelates for magnetic resonance imaging. Chem Rev (2010) 2.25
Mitochondrial localization of estrogen receptor beta. Proc Natl Acad Sci U S A (2004) 2.15
Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell (2013) 1.71
Increased beta-secretase activity and expression in rats following transient cerebral ischemia. Brain Res (2004) 1.59
Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J Biol Chem (2011) 1.41
Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection. Proc Natl Acad Sci U S A (2003) 1.37
Testosterone increases neurotoxicity of glutamate in vitro and ischemia-reperfusion injury in an animal model. J Appl Physiol (1985) (2002) 1.35
Estrogen attenuates nuclear factor-kappa B activation induced by transient cerebral ischemia. Brain Res (2004) 1.29
Estrogens and progesterone as neuroprotectants: what animal models teach us. Front Biosci (2008) 1.25
Estrogens directly potentiate neuronal L-type Ca2+ channels. Proc Natl Acad Sci U S A (2008) 1.22
Multi-frequency PARACEST agents based on europium(III)-DOTA-tetraamide ligands. Angew Chem Int Ed Engl (2009) 1.20
Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats. Biochim Biophys Acta (2006) 1.20
17beta-Estradiol attenuates blood-brain barrier disruption induced by cerebral ischemia-reperfusion injury in female rats. Brain Res (2005) 1.18
Neuroprotective effects of an estratriene analog are estrogen receptor independent in vitro and in vivo. Brain Res (2005) 1.16
Sohlh2 knockout mice are male-sterile because of degeneration of differentiating type A spermatogonia. Stem Cells (2008) 1.15
Oxidative damage to human lens epithelial cells in culture: estrogen protection of mitochondrial potential, ATP, and cell viability. Invest Ophthalmol Vis Sci (2003) 1.15
Europium(III) DOTA-tetraamide complexes as redox-active MRI sensors. J Am Chem Soc (2012) 1.15
Novel mechanisms for estrogen-induced neuroprotection. Exp Biol Med (Maywood) (2006) 1.09
Role of PPAR-gamma ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells. Invest Ophthalmol Vis Sci (2003) 1.09
T2 exchange agents: a new class of paramagnetic MRI contrast agent that shortens water T2 by chemical exchange rather than relaxation. Magn Reson Med (2011) 1.09
Structure-nongenomic neuroprotection relationship of estrogens and estrogen-derived compounds. Pharmacol Ther (2007) 1.09
Transient cerebral ischemia induces site-specific hyperphosphorylation of tau protein. Brain Res (2004) 1.08
Transient cerebral ischemia induces aberrant neuronal cell cycle re-entry and Alzheimer's disease-like tauopathy in female rats. J Biol Chem (2004) 1.07
Neuroprotective effects of 17beta-estradiol and nonfeminizing estrogens against H2O2 toxicity in human neuroblastoma SK-N-SH cells. Mol Pharmacol (2006) 1.06
Estrogen protects the inner retina from apoptosis and ischemia-induced loss of Vesl-1L/Homer 1c immunoreactive synaptic connections. Invest Ophthalmol Vis Sci (2003) 1.05
Reversing the Warburg effect as a treatment for glioblastoma. J Biol Chem (2013) 1.02
Estrogen receptor beta as a mitochondrial vulnerability factor. J Biol Chem (2009) 1.02
Combination therapy of 17beta-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke. J Pharmacol Exp Ther (2009) 1.02
Mechanistic investigations on the antioxidant action of a neuroprotective estrogen derivative. Steroids (2007) 1.02
Rapid mitochondrial dysfunction mediates TNF-alpha-induced neurotoxicity. J Neurochem (2015) 1.01
Neuroprotective effects of a novel non-receptor-binding estrogen analogue: in vitro and in vivo analysis. Stroke (2002) 1.01
Spermatogonial culture medium: an effective and efficient nutrient mixture for culturing rat spermatogonial stem cells. Biol Reprod (2009) 1.00
A prototypical Sigma-1 receptor antagonist protects against brain ischemia. Brain Res (2007) 0.99
Neuroprotective actions of methylene blue and its derivatives. PLoS One (2012) 0.99
Subcellular distribution of native estrogen receptor alpha and beta subtypes in cultured human lens epithelial cells. Exp Eye Res (2004) 0.97
Dose dependence and therapeutic window for the neuroprotective effects of 17beta-estradiol when administered after cerebral ischemia. Neurosci Lett (2007) 0.96
Glutamate receptor activation evokes calpain-mediated degradation of Sp3 and Sp4, the prominent Sp-family transcription factors in neurons. J Neurochem (2007) 0.96
The use of estrogens and related compounds in the treatment of damage from cerebral ischemia. Ann N Y Acad Sci (2003) 0.95
Role of protein phosphatases in estrogen-mediated neuroprotection. J Neurosci (2005) 0.95
The effect of atrazine administered by gavage or in diet on the LH surge and reproductive performance in intact female Sprague-Dawley and Long Evans rats. Birth Defects Res B Dev Reprod Toxicol (2014) 0.93
Estrogen protection in Friedreich's ataxia skin fibroblasts. Endocrinology (2011) 0.92
Neuroendocrine mechanism for tolerance to cerebral ischemia-reperfusion injury in male rats. J Neurobiol (2005) 0.91
Estrogens as protectants of the neurovascular unit against ischemic stroke. Curr Drug Targets CNS Neurol Disord (2005) 0.91
Neuroprotective effects of PPARgamma agonists against oxidative insults in HT-22 cells. Eur J Pharmacol (2003) 0.91
An okadaic acid-induced model of tauopathy and cognitive deficiency. Brain Res (2010) 0.90
Proestrus levels of estradiol during transient global cerebral ischemia improves the histological outcome of the hippocampal CA1 region: perfusion-dependent and-independent mechanisms. J Neurol Sci (2002) 0.89
Estrogen receptor-independent neuroprotection via protein phosphatase preservation and attenuation of persistent extracellular signal-regulated kinase 1/2 activation. J Pharmacol Exp Ther (2007) 0.89
Cell-cycle regulators are involved in transient cerebral ischemia induced neuronal apoptosis in female rats. FEBS Lett (2005) 0.88
Ethanol withdrawal posttranslationally decreases the activity of cytochrome c oxidase in an estrogen reversible manner. Neurosci Lett (2007) 0.88
Estradiol protects against cerebellar damage and motor deficit in ethanol-withdrawn rats. Alcohol (2002) 0.88
Okadaic acid induces tau phosphorylation in SH-SY5Y cells in an estrogen-preventable manner. Brain Res (2010) 0.87
Estrogen treatment following severe burn injury reduces brain inflammation and apoptotic signaling. J Neuroinflammation (2009) 0.87
The assessment of non-feminizing estrogens for use in neuroprotection. Brain Res (2010) 0.87
Estrone is neuroprotective in rats after traumatic brain injury. J Neurotrauma (2012) 0.87
Transient focal cerebral ischemia induces long-term cognitive function deficit in an experimental ischemic stroke model. Neurobiol Dis (2013) 0.86
Estrogen protects against brain lipid peroxidation in ethanol-withdrawn rats. Pharmacol Biochem Behav (2004) 0.86
Ethanol withdrawal acts as an age-specific stressor to activate cerebellar p38 kinase. Neurobiol Aging (2010) 0.85
Estrogen prevents oxidative damage to the mitochondria in Friedreich's ataxia skin fibroblasts. PLoS One (2012) 0.85
Role of nonfeminizing estrogen analogues in neuroprotection of rat retinal ganglion cells against glutamate-induced cytotoxicity. Free Radic Biol Med (2005) 0.85
Noninvasive monitoring of estrogen effects against ischemic stroke in rats by near-infrared spectroscopy. Appl Opt (2007) 0.84
Modulation of polymorphonuclear neutrophil functions by astrocytes. J Neuroinflammation (2010) 0.84
Divergent mechanisms for trophic actions of estrogens in the brain and peripheral tissues. Brain Res (2010) 0.84
Protein phosphatase 1, protein phosphatase 2A, and calcineurin play a role in estrogen-mediated neuroprotection. Endocrinology (2008) 0.84
Mechanism of okadaic acid-induced neuronal death and the effect of estrogens. J Neurochem (2008) 0.83
Neuroprotective effects of high affinity Σ1 receptor selective compounds. Brain Res (2011) 0.83
17beta-Estradiol extends ischemic thresholds and exerts neuroprotective effects in cerebral subcortex against transient focal cerebral ischemia in rats. Brain Res (2003) 0.83
Potentiation of spinal alpha(2)-adrenoceptor analgesia in rats deficient in TRPV1-expressing afferent neurons. Neuropharmacology (2007) 0.83
Therapeutic strategies in Friedreich's ataxia. Brain Res (2013) 0.82
nNOS is involved in estrogen mediated neuroprotection in neuroblastoma cells. Neuroreport (2004) 0.82
Quinol-based metabolic cycle for estrogens in rat liver microsomes. Drug Metab Dispos (2003) 0.82
Neuroprotective effects of nonfeminizing estrogens in retinal photoreceptor neurons. Invest Ophthalmol Vis Sci (2012) 0.81
Hippocampal progenitor cells express nestin following cerebral ischemia in rats. Neuroreport (2005) 0.81
Ethanol withdrawal hastens the aging of cytochrome c oxidase. Neurobiol Aging (2011) 0.81
Intermittent hypoxia conditioning prevents behavioral deficit and brain oxidative stress in ethanol-withdrawn rats. J Appl Physiol (1985) (2008) 0.81
Involvement of estrogen receptor β5 in the progression of glioma. Brain Res (2013) 0.81
A-single spermatogonia heterogeneity and cell cycles synchronize with rat seminiferous epithelium stages VIII-IX. Biol Reprod (2014) 0.81
Pyruvate enhances neurological recovery following cardiopulmonary arrest and resuscitation. Resuscitation (2007) 0.81
Role of the GABAA system in behavioral, motoric, and cerebellar protection by estrogen during ethanol withdrawal. Alcohol (2003) 0.81
Role of the GABA-A system in estrogen-induced protection against brain lipid peroxidation in ethanol-withdrawn rats. Alcohol Clin Exp Res (2004) 0.81
Correspondence regarding Schwend and Gustafsson, "False positives in MALDI-TOF detection of ERbeta in mitochondria". Biochem Biophys Res Commun (2006) 0.80
Neuroprotection with non-feminizing estrogen analogues: an overlooked possible therapeutic strategy. Horm Behav (2012) 0.80
Role of protein kinase C in estrogen protection against apoptotic cerebellar cell death in ethanol-withdrawn rats. Alcohol (2003) 0.80
A nonfeminizing estrogen analog protects against ethanol withdrawal toxicity in immortalized hippocampal cells. J Pharmacol Exp Ther (2006) 0.80
A potent antioxidant small molecule aimed at targeting metal-based oxidative stress in neurodegenerative disorders. Chem Commun (Camb) (2013) 0.80
Role of parvalbumin in estrogen protection from ethanol withdrawal syndrome. Alcohol Clin Exp Res (2005) 0.80
Ethanol withdrawal provokes mitochondrial injury in an estrogen preventable manner. J Bioenerg Biomembr (2008) 0.80
Simultaneous quantification of four native estrogen hormones at trace levels in human cerebrospinal fluid using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal (2010) 0.79
Ethanol withdrawal provokes opening of the mitochondrial membrane permeability transition pore in an estrogen-preventable manner. J Pharmacol Exp Ther (2008) 0.79
Increased severity of acute cerebral ischemic injury correlates with enhanced stem cell induction as well as with predictive behavioral profiling. Curr Neurovasc Res (2004) 0.79
Electronic effects of (N2S2)M(NO) complexes (M = Fe, Co) as metallodithiolate ligands. Inorg Chem (2008) 0.79
Consortium for the Assessment of Research on Progestins and Estrogens (CARPE) Fort Worth, Texas August 1-3, 2003. J Womens Health (Larchmt) (2004) 0.78
Window of opportunity for estrogen and progestin intervention in brain aging and Alzheimer's disease. Brain Res (2013) 0.78
Phenolic compounds protect cultured hippocampal neurons against ethanol-withdrawal induced oxidative stress. Int J Mol Sci (2009) 0.78